In spite of the fact that both diseases share a chronic inflammatory condition as the hallmark of their clinical course, we found higher levels and a higher prevalence of IgA AZA antibodies in the CD patient group compared to in IBS patients and healthy controls, suggesting that the genetic susceptibility in CD influences the immunological response to other dietary prolamins besides gliadin in some celiac patients. The gene discussed is CD79A; the disease is irritable bowel syndrome.